p53 transcriptional pathways in breast cancer: The good, the bad and the complex

Journal of Pathology

Volumn 220, Issue 4, 2010, Pages 401-403

  Thompson, Alastair M ^a   Lane, David P ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

Bcl2; Breast cancer; Immunohistochemistry; Mdm2; P21; p53; Prognosis; Signature

Indexed keywords

ANTHRACYCLINE DERIVATIVE; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MISSENSE MUTATION; NONHUMAN; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; GENES, P53; HUMANS; PROGNOSIS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 76749155505     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2674     Document Type: Note

References (25)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-16.
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-283.
3. Hollstein M, Hainaut P. Massively regulated genes: the example of TP53 . J Pathol 2010;[ARI issue; Epub ahead of print, 13 November 2009].
4. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9:862-873.
5. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res 2006;12:1157-1167.
6. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, et al. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-2751.
7. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-1034.
8. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
9. Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-5588.
10. Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008;75:132-139.
11. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071-1078.
12. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-56.
13. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathological parameters. Int J Cancer 1992;50:528-532.
14. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614.
15. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008;47:600-607.
16. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714-723.
17. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005;102:13550-13555.
18. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527.
19. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-259.
20. Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice M, Blamey RW, Lopez-Garcia MA, et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2009;DOI:10.1002/path.2663.
21. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009;9:307-310.
22. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-2137.
23. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonize cell differentiation and response to stress. Cell Death Differ 2006;13:962-972.
24. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-1692.
25. Vousden KH. Functions of p53 in metabolism and invasion. Biochem Soc Trans 2009;37:511-517.